The Critical Roles of the SUMO-Specific Protease SENP3 in Human Diseases and Clinical Implications

• Main Authors: Xiaojun Long, Biying Zhao, Wenbin Lu, Xu Chen, Xinyi Yang, Jifang Huang, Yuhong Zhang, Siming An, Yuanyuan Qin, Zhengcao Xing, Yajie Shen, Hongmei Wu, Yitao Qi
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2020-10-01
• Series: Frontiers in Physiology
• Subjects: SUMOylation; SENP3; cancer; neurological disease; cardiovascular disease
• Online Access: https://www.frontiersin.org/articles/10.3389/fphys.2020.558220/full

Post-translational modification by SUMO (small ubiquitin-like modifier) proteins has been shown to regulate a variety of functions of proteins, including protein stability, chromatin organization, transcription, DNA repair, subcellular localization, protein–protein interactions, and protein homeostasis. SENP (sentrin/SUMO-specific protease) regulates precursor processing and deconjugation of SUMO to control cellular mechanisms. SENP3, which is one of the SENP family members, deconjugates target proteins to alter protein modification. The effect of modification via SUMO and SENP3 is crucial to maintain the balance of SUMOylation and guarantee normal protein function and cellular activities. SENP3 acts as an oxidative stress-responsive molecule under physiological conditions. Under pathological conditions, if the SUMOylation process of proteins is affected by variations in SENP3 levels, it will cause a cellular reaction and ultimately lead to abnormal cellular activities and the occurrence and development of human diseases, including cardiovascular diseases, neurological diseases, and various cancers. In this review, we summarized the most recent advances concerning the critical roles of SENP3 in normal physiological and pathological conditions as well as the potential clinical implications in various diseases. Targeting SENP3 alone or in combination with current therapies might provide powerful targeted therapeutic strategies for the treatment of these diseases.